BioSpace News Archive

Cardiovascular diseases affects over 3 million Canadians, and over 750, 000 Canadians are living with heart failure.

RadNet, Inc. announced that it will host a conference call to discuss its fourth quarter 2022 financial results on Tuesday, February 28, 2023 at 7:30 a.m. Pacific Time.

The drug ApTOLL, developed by the biopharmaceutical company aptaTargets, yielded groundbreaking safety and efficacy results in a Phase 1b/2a clinical trial in patients with acute ischemic stroke in combination with endovascular therapy (EVT).

Tikcro Technologies Ltd. announced the declaration of a liquidating cash dividend in the aggregate amount of $3,017,270, or $0.305 per share, without interest and subject to applicable withholding requirements.

ANGLE plc, a world-leading liquid biopsy company, announces that, on 09 February 2023, it has been notified that Andrew Newland, Chief Executive Officer, purchased 125,000 ordinary shares of 10 pence each at a price of 28.75 pence each.

Guerbet, a global specialist in contrast agents and solutions for medical imaging, has reported its annual revenue.

For decades, people with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) have faced multiple obstacles.

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) today announced regulatory updates for its approved products, VOQUEZNA™ TRIPLE PAK™ and VOQUEZNA DUAL PAK™, approved in the U.S. for the treatment of H. pylori infection, and its pending New Drug Application (NDA) for vonoprazan for the treatment of erosive esophagitis.

Sensus Healthcare, Inc. announces financial results for the three and 12 months ended December 31, 2022.

Personalis, Inc., a leader in advanced genomics for precision oncology, announced that it will release its fourth quarter and full year 2022 financial results on Thursday, February 23, 2023.